In the first quarter of the year, the company reported bumper revenue due to strong drug demand

AstraZeneca has 'much business momentum and news upcoming' alongside a 'broad and deep' pipeline of drugs, according to broker TD Cowen.

The pharmaceutical giant reported total turnover climbed by $1.8billion at constant exchange rates to $12.7billion (£10.2billion) in the opening three months of 2024.

AstraZeneca continued to see strong earnings boosted primarily by its oncology branch, as well as its respiratory and immunology segment.